Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer along with or even without brain metastases: a phase 3b\/4 trial

.Nature Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ advanced bosom cancer cells and also active or stable human brain metastases presented consistent intracranial activity and systemic efficiency of T-DXd.